Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Tantrums

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44335   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    6 result(s) found for: Tantrums. Displaying page 1 of 1.
    EudraCT Number: 2016-005111-40 Sponsor Protocol Number: CN138-178 Start Date*: 2017-04-07
    Sponsor Name:Otsuka Pharmaceutical Development & Commercialization, Inc
    Full Title: A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Flexible- Dosed Parallel-Group Study of Aripiprazole Flexibly Dosed in the Treatment of Children and Adolescents with Autistic Disorder
    Medical condition: Autistic Disorder
    Disease:
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2017-000174-11 Sponsor Protocol Number: CN138603 Start Date*: 2017-04-07
    Sponsor Name:Otsuka Pharmaceutical Development & Commercialization, Inc
    Full Title: Safety and Efficacy of Aripiprazole in the Long-Term Maintenance Treatment of Pediatric Subjects with Irritability Associated with Autistic Disorder
    Medical condition: Irritability in Autism Disorder
    Disease:
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2020-000867-21 Sponsor Protocol Number: NGAM-13 Start Date*: 2021-08-16
    Sponsor Name:Octapharma Pharmazeutika Produktionsges.m.b.H.
    Full Title: A Superiority Study To Compare The Effect of Panzyga Versus Placebo in Patients with Pediatric Acute-onset Neuropsychiatric Syndrome
    Medical condition: Pediatric Acute-Onset Neuropsychiatric Syndrome (PANS). PANS is a research diagnosis given to patients who have an abrupt, dramatic onset of neuropsychiatric symptoms including obsessions/compulsio...
    Disease:
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA SE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2016-003820-22 Sponsor Protocol Number: 2016-Longterm-OX Start Date*: 2016-12-22
    Sponsor Name:Dutch Growth Research Foundation
    Full Title: Intranasal administration of oxytocin in children with Prader-Willi Syndrome. A randomized, open-label, cross-over trial of different treatment regimens of oxytocin administration. Effects on eatin...
    Medical condition: Prader-Willi syndrome
    Disease: Version SOC Term Classification Code Term Level
    19.0 10010331 - Congenital, familial and genetic disorders 10036476 Prader-Willi syndrome PT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: NL (Not Authorised)
    Trial results: (No results available)
    EudraCT Number: 2017-003423-30 Sponsor Protocol Number: 2017-RCT-OX Start Date*: 2017-12-12
    Sponsor Name:Dutch Growth Research Foundation
    Full Title: Randomized, double-blind, placebo-controlled oxytocin and dose-response trial in children with Prader-Willi syndrome. Effects on social behaviour.
    Medical condition: Prader-Willi syndrome
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10036476 Prader-Willi syndrome PT
    Population Age: Children, Under 18 Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2006-005346-37 Sponsor Protocol Number: F1D-MC-HGMR Start Date*: Information not available in EudraCT
    Sponsor Name:Eli Lilly and Company Limited
    Full Title: A Randomized, Double-Blind, Placebo-Controlled Maintenance of Effect Study of Olanzapine in the Treatment of Disruptive Behavioral Symptoms in Children and Adolescents with Pervasive Developmental ...
    Medical condition: children and adolescents with disruptive behavioral symptoms associated with Pervasive Developmental Disorders (PDD)
    Disease: Version SOC Term Classification Code Term Level
    8.1 10061345 Pervasive developmental disorder LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Wed May 14 06:47:04 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA